Trials / Recruiting
RecruitingNCT06723990
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
Prospective Observational Monocentric Study to Evaluate the Impact of the HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2-BREAST-DX
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- European Institute of Oncology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neoadjuvant standard treatment for HER2+ | NEOADJUVANT SETTING |
| DRUG | Adjuvant standard treatment for HER2+ | ADJUVANT SETTING |
Timeline
- Start date
- 2024-10-24
- Primary completion
- 2027-11-01
- Completion
- 2027-11-01
- First posted
- 2024-12-09
- Last updated
- 2026-02-11
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06723990. Inclusion in this directory is not an endorsement.